US · CMPS
COMPASS Pathways plc
- Sector
- Healthcare · Medical - Care Facilities
- Headquarters
- London W1F 0DQ
- Website
- compasspathways.com
Price · as of 2024-12-31
$9.01
Market cap 662.41M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $41.30 | ||||
| 2021 | $12.15 | ||||
| 2022 | $7.75 | ||||
| 2023 | $10.88 | ||||
| 2024 | $3.74 |
AI valuation
Our deep-learning model estimates COMPASS Pathways plc's (CMPS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $9.01
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CMPS | COMPASS Pathways plc | $9.01 | 662.41M | — | — | — | — | -1.63 | 1.63 | — | -0.80 | — | 1.63 | 0.00% | — | — | -81.55% | -590.05% | -63.36% | 0.21 | -39.79 | 5.92 | 5.49 | 0.89 | -86.00% | — | 2231.00% | -47.22% | -3.50 | -394.64% | 0.00% | 0.00% | 0.00% | -0.67 | -1.00 | — | -2.75 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| CYH | Community Health Systems,… | $3.46 | 479.28M | +184% | -61% | — | +667% | 0.67 | -0.33 | 0.04 | 5.83 | — | -0.09 | 8.67% | -79.42% | 4.08% | -40.87% | -92.22% | 4.96% | -8.31 | -11.40 | 1.46 | 1.06 | 5.60 | -19667.00% | -118.00% | 7333.00% | 45.79% | 0.25 | 2.07% | 0.00% | 0.00% | 164.44% | -1.19 | 56.61 | 0.94 | -1.80 |
| EHAB | Enhabit, Inc. | $13.61 | 689.9M | +90% | -75% | — | — | -2.78 | 0.82 | 0.41 | -11.59 | -2.98 | -0.99 | 48.71% | -11.12% | -15.09% | -25.81% | -9.68% | -11.58% | 1.09 | -2.68 | 1.53 | 1.41 | -6.47 | 9317.00% | -110.00% | 557.00% | 11.07% | 0.41 | 4.09% | 0.00% | 0.00% | 9.71% | -8.42 | 20.45 | 0.94 | 1.09 |
| FDMT | 4D Molecular Therapeutics… | $9.66 | 492.74M | +142% | -52% | — | +2,596% | -1.36 | 0.43 | 5933.81 | 1.00 | -8.80 | 0.43 | 100.00% | -507678.38% | -434778.38% | -39.31% | -259.80% | -35.74% | 0.05 | — | 14.92 | 14.58 | 0.69 | 1550.00% | -9982.00% | 7613.00% | -63.02% | -4.62 | -191.38% | 0.00% | 0.00% | 0.00% | 0.96 | 1.31 | -4884.32 | 0.97 |
| GOSS | Gossamer Bio, Inc. | $0.42 | 98.35M | — | +201% | — | — | -4.84 | 9.28 | 2.39 | -4.56 | — | 9.28 | 100.00% | -52.24% | -49.28% | -122.54% | 143.80% | -18.03% | 6.88 | -5.20 | 6.88 | 6.66 | -3.92 | -7881.00% | — | -9782.00% | -1.27% | -0.08 | 8.32% | 0.00% | 0.00% | 8.83% | -3.04 | -52.51 | 1.59 | -4.31 |
| KALV | KalVista Pharmaceuticals,… | $16.28 | 822.89M | — | — | — | — | -3.93 | 7.56 | — | -3.11 | -54.08 | 7.56 | 0.00% | — | — | -121.50% | 456.02% | -75.46% | 0.07 | -32.50 | 5.35 | 4.49 | 0.53 | 727.00% | — | 7100.00% | -21.27% | -3.39 | 371.96% | 0.00% | 0.00% | 9.41% | -2.87 | -3.52 | — | -2.40 |
| PRTA | Prothena Corporation plc | $8.67 | 466.71M | +225% | -47% | — | +4,117% | -2.07 | 1.80 | 52.25 | -1.06 | -2.08 | 1.80 | 0.00% | -1905.82% | -2520.57% | -63.62% | -2799.76% | -55.86% | 0.05 | — | 7.72 | 7.53 | 1.46 | 9956.00% | -9283.00% | 889.00% | -32.36% | -4.01 | -2483.59% | 0.00% | 0.00% | 0.00% | -1.15 | -1.30 | 21.92 | 5.73 |
| SNDA | Sonida Senior Living, Inc… | $35.89 | 673.64M | +237% | +24% | -86% | — | -105.95 | 2.82 | 1.14 | 12.59 | — | 3.53 | 89.12% | -4.87% | -0.68% | -11.61% | -2.25% | -0.45% | 5.29 | -0.40 | 0.85 | 0.48 | 8.13 | -8597.00% | 1919.00% | 27150.00% | -7.76% | -0.02 | -4.10% | 0.81% | -85.90% | 0.81% | -66.20 | -36.43 | 3.23 | -0.12 |
| TALK | Talkspace, Inc. | $4.82 | 807.19M | +644% | +552% | -81% | -72% | -159.22 | 7.10 | 3.63 | 65.62 | -30.89 | 7.30 | 42.97% | 1.38% | 3.40% | -4.45% | 24.45% | -3.81% | 0.00 | — | 6.38 | 6.25 | -3.32 | 51538.00% | 2200.00% | -13365.00% | -0.25% | 0.49 | -17.55% | 0.00% | 0.00% | 2.07% | 234.06 | -350.15 | 3.22 | 27.81 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
- CEO
- Kabir Kumar Nath
- Employees
- 166
- Beta
- 1.93
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $9.01) − 1 = — (DCF, example).